The legal action, spearheaded by Robbins LLP, centers on claims that Erasca failed to disclose significant risks involving its preclinical data. Specifically, the complaint alleges that the company utilized improper comparisons between its ERAS-0015 treatment and products developed by Revolution Medicines, Inc. These practices purportedly exposed the company to serious patent infringement and trade secret misappropriation claims, undermining the validity of positive public statements made by executives during the class period.

Market confidence wavered on April 27, 2026, after Erasca filed a Form 8-K acknowledging a formal complaint from Revolution Medicines. The disclosure detailed demands for Erasca to cease making deceptive comparative statements regarding its drug candidate and the RMC-6236 therapy. Following the news, Erasca's stock price dropped from $21.49 to $19.15 per share. While Erasca maintains that the allegations are meritless and intends to defend its position in court, shareholders seeking to serve as lead plaintiff must submit their filings by August 10, 2026.